Kinases are a large class of enzymes that are crucial to the proper operation of many cellular processes including cell growth, metabolism and apoptosis. Protein kinases use ATP to phosphorylate proteins within a cell, modifying the target protein’s function in some manner. Since abnormally functioning protein kinases are involved in the pathogenesis of many diseases, these enzymes are often drug therapy targets. Protein kinase inhibitors are small molecules, polypeptides, or antibodies that block or diminish kinase function. In research, they are often used in kinase inhibition assays, ultimately leading to the identification of appropriate therapeutic targets and the development of effective treatments. There is a growing list of FDA-approved kinase inhibitor drugs that treat a myriad of diseases such as cancer, autoimmune disorders, inflammatory disorders, and glaucoma. Some examples include:
MEK Inhibitors - BRAF-V600E positive advanced melanoma (Trametinib)
JAK Inhibitors - myelofibrosis (Ruxolitinib)
PI3K Inhibitors - Chronic lymphocytic leukemia (Idelalisib)
Advances have moved the needle in what is possible in PTM detection
Multi-omics analysis is growing because more information is better.
We used this Wortmannin to inhibit PI3K and other it's role in other ...
In our cell culture, Trypsin inhibitors are used in cell culture experiments to ...
The R230 Focused-ultrasonicator is the next generation AFA powered instrument ...
Recombinant REAfinity™ Antibodies for reproducible flow cytometry results ...